Distinction of Pulmonary Large Cell Neuroendocrine Carcinoma from Small Cell Lung Carcinoma Using a Panel of Bcl-2, p63, and 34βE12
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background: Making the distinction between large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) is difficult in some samples of biopsy tissues, but we have to separate LCNEC from SCLC because the two types of cancer may need different therapy and they have different prognostic implications. Thus far, there are no specific immunohistochemical markers that allow distinguishing these two kinds of tumors. Methods: We performed an immunohistochemical analysis to study the expressions of p63, Bcl-2, and 34βE12 and to investigate whether these 3 molecules have correlations in LCNEC and SCLC. We also evaluated the expression of the neuroendocrine markers chromogranin, synaptophysin and CD56. Results: A statistical analysis was performed for p63, Bcl-2, and 34βE12 in separate and combined panels. According to the combinations of p63, Bcl-2, and 34βE12, there were frequent expressions of p63-/Bcl-2+ or Bcl-2+/34βE12- in the SCLC, and there was a superior proportion of them in the SCLC rather than that in the LCNEC. The p63-/Bcl-2+ and Bcl-2+/34βE12- antibody combinations showed higher specificities compared to any single antibody for diagnosing SCLC. Conclusions: Bcl-2 and selective p63 or 34βE12 made up a most useful panel of markers for making the differential diagnosis of LCNEC and SCLC.
Abstract
Background: Making the distinction between large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) is difficult in some samples of biopsy tissues, but we have to separate LCNEC from SCLC because the two types of cancer may need different therapy and they have different prognostic implications. Thus far, there are no specific immunohistochemical markers that allow distinguishing these two kinds of tumors. Methods: We performed an immunohistochemical analysis to study the expressions of p63, Bcl-2, and 34βE12 and to investigate whether these 3 molecules have correlations in LCNEC and SCLC. We also evaluated the expression of the neuroendocrine markers chromogranin, synaptophysin and CD56. Results: A statistical analysis was performed for p63, Bcl-2, and 34βE12 in separate and combined panels. According to the combinations of p63, Bcl-2, and 34βE12, there were frequent expressions of p63-/Bcl-2+ or Bcl-2+/34βE12- in the SCLC, and there was a superior proportion of them in the SCLC rather than that in the LCNEC. The p63-/Bcl-2+ and Bcl-2+/34βE12- antibody combinations showed higher specificities compared to any single antibody for diagnosing SCLC. Conclusions: Bcl-2 and selective p63 or 34βE12 made up a most useful panel of markers for making the differential diagnosis of LCNEC and SCLC.
참고문헌 (16)
- Travis WD, "Advances in neuroendocrine lung tumors", Ann Oncol, 21(Suppl 7), pp.vii65~vii71 (2010)
- Hiroshima K, "Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis", Mod Pathol, 19, pp.1358~1368 (2006)
- Asamura H, "Neuroendocrine neoplasms of the lung: a prognostic spectrum", J Clin Oncol, 24, pp.70~76 (2006)
- Nagashio R, "Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas", Pathol Int, 60, pp.71~77 (2010)
- Nitadori J, "Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel", Am J Clin Pathol, 125, pp.682~692 (2006)
- Song J, "Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung", Arch Pathol Lab Med, 134, pp.1702~1705 (2010)
- Massion PP, "Significance of p63 amplification and overexpression in lung cancer development and prognosis", Cancer Res, 63, pp.7113~7121 (2003)
- Wu M, "p63 and TTF-1 immunostaining: a useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung", Am J Clin Pathol, 119, pp.696~702 (2003)
- Au NH, "P63 expression in lung carcinoma: a tissue microarray study of 408 cases", Appl Immunohistochem Mol Morphol, 12, pp.240~247 (2004)
- Sturm N, "34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma", Histopathology, 42, pp.156~166 (2003)
- Sturm N, "Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung", Hum Pathol, 32, pp.918~925 (2001)
- Rossi G, "TTF-1, cytokeratin 7, 34betaE12, and CD56", NCAM immunostaining in the subclassification of large cell carcinomas of the lung, 2004, pp.122, 884~893
- Lyda MH, "Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas", Hum Pathol, 31, pp.980~987 (2000)
- Viberti L, "34betaE12 Cytokeratin Immunodetection in the Differential Diagnosis of Small Cell Tumors of Lung", Int J Surg Pathol, 8, pp.317~322 (2000)
- Shy SW, "Small cell lung carcinoma: clinicopathological, immunohistochemical, and ultrastructural study", J Surg Oncol, 45, pp.146~161 (1990)
- Rekhtman N, "Neuroendocrine tumors of the lung: an update", Arch Pathol Lab Med, 134, pp.1628~1638 (2010)